Retrospective Evaluation of an Observational Cohort by the Central and Eastern Europe Network Group Shows a High Frequency of Potential Drug–Drug Interactions Among HIV-Positive Patients Receiving Treatment for Coronavirus Disease 2019 (COVID-19)

Botond Lakatos; Justyna Kowalska; Sergii Antoniak; Deniz Gokengin; Josip Begovac; Anna Vassilenko; Piotr Wasilewski; Lukas Fleischhans; David Jilich; Raimonda Matulionyte; Kerstin Kase; Antonios Papadopoulus; Nino Rukhadze; Arjan Harxhi; Sam Hofman; Gordana Dragovic; Marta Vasyliev; Antonija Verhaz; Nina Yancheva; Cristiana Oprea


HIV Medicine. 2022;23(6):693-700. 

In This Article


The Euroguidelines in Central and Eastern Europe (ECEE) Network Group initiative was founded in 2016 primarily to compare and improve national protocols for HIV and hepatitis in the region.[8] With the benefit of the network of infectious diseases clinicians working on the frontline of the pandemic, who were thus reliable first-hand data providers, the ECEE Network Group initiated a retrospective, observational cohort study of HIV-positive patients diagnosed with SARS-CoV-2 infection. Data were collected between 12 November 2020 and 14 May 2021 and analysed using descriptive statistics. In this international multicentre study, we applied a standardized online questionnaire with 33 standardized questions. In total, 24 centres from 16 countries provided answers, mainly in Central and Eastern Europe, including Albania, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, the Czech Republic, Estonia, Georgia, Greece, Hungary, Lithuania, Poland, Romania, Serbia, Turkey and Ukraine. All patients who received cART at the time of COVID-19 onset were included in the analyses. All potential DDIs were reviewed for patients receiving cART and specific COVID-19 treatment using the interaction checker platform at the University of Liverpool.[9,10]